One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
OrthoPediatrics Corp. logo
OrthoPediatrics Corp. KIDS
$ 31.72 -1.18%
report update icon

Quarterly report 2026-Q3
added 10-28-2026

OrthoPediatrics Corp. Financial Statements 2025-2011 | KIDS

Annual Financial Statements OrthoPediatrics Corp.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

437 M 589 M 620 M 911 M 1.15 B 745 M 695 M 440 M 83.3 M - - - - - -

Shares

23.5 M 23.1 M 22.7 M 20.7 M 19.3 M 18.1 M 14.6 M 12.6 M 4.82 M - - - - - -

Historical Prices

18.6 25.5 27.4 44 59.9 41.2 47 34.9 19.2 - - - - - -

Net Income

-39.6 M -37.8 M -21 M 1.26 M -16.3 M -32.9 M -13.7 M -12 M -8.93 M -6.57 M -7.89 M -9.55 M - - -

Revenue

236 M 205 M 149 M 122 M 98 M 71.1 M 72.6 M 57.6 M 45.6 M 37.3 M 31 M 23.7 M - - -

Cost of Revenue

63.7 M 56.1 M 37.5 M 31.6 M 24.6 M 16 M 17.9 M 14.9 M 11.2 M 10.9 M 9.37 M - - - -

Gross Profit

173 M 149 M 111 M 90.7 M 73.4 M 55 M 54.6 M 42.7 M 34.4 M 26.4 M 21.6 M 16.6 M - - -

Operating Income

-39.2 M -35 M -26.8 M -25.4 M -18 M -26.8 M -9.08 M -9.55 M -6.47 M -6.13 M -6.59 M - - - -

Interest Expense

6.05 M -1.07 M 2.26 M -1.8 M 1.08 M 20 K 3.54 M 2.26 M 2.49 M 1.48 M 1.23 M - - - -

EBITDA

-18.1 M -15.9 M -9.37 M -12.3 M -7.34 M -18.7 M -4.41 M -6.66 M -4.07 M -4.22 M -4.74 M -5.57 M - - -

Operating Expenses

212 M 184 M 138 M 116 M 91.4 M 81.8 M 63.7 M 52.2 M 40.9 M 32.5 M 28.2 M 23.7 M - - -

General and Administrative Expenses

120 M 103 M 73.3 M 57.9 M 46.1 M 38.3 M 26.7 M 20.9 M 17 M 13.6 M 11.4 M 9.88 M - - -

All numbers in USD currency

Quarterly Income Statement OrthoPediatrics Corp.

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

24.2 M 24 M 23.7 M - 23.6 M 23.5 M 23.2 M 31.5 M 23.2 M 23.1 M 22.8 M 29.4 M 22.8 M 22.7 M 22.5 M 22.9 M 21.2 M 19.8 M 19.4 M 19.7 M 19.3 M 19.3 M 19.2 M 19.6 M 19.1 M 17.5 M 16.4 M 16.7 M 14.6 M 14.5 M 14.4 M 14.5 M 12.6 M 12.5 M 12.1 M 2.26 M 1.77 M 1.75 M 1.74 M 2.42 M 1.74 M - - - - - - - - - - - - - - - - - - - - - -

Net Income

-5.93 M -7.16 M -10.7 M - -11.8 M -7.11 M -10.7 M - -7.92 M -6.03 M -7.8 M -6.69 M -4.59 M -2.89 M -6.81 M - 18.5 M -333 K -9.1 M 72 K -2.2 M -3.76 M -10.4 M -14 M -4.54 M -9.45 M -4.94 M -5.43 M -2.66 M -2.62 M -3.02 M -2.47 M -1.86 M -2.69 M -5 M -15.1 M -3.02 M -1.27 M -1.28 M -3.63 M -846 K -288 K -1.8 M - - - - - - - - - - - - - - - - - - - -

Revenue

72.7 M 70.5 M 59.4 M - 61.2 M 61.1 M 52.4 M 52.7 M 54.6 M 52.8 M 44.7 M 37.6 M 40 M 39.6 M 31.6 M - 35 M 32.9 M 23.4 M 24.8 M 25.1 M 26.7 M 21.5 M 18.9 M 22.2 M 13.6 M 16.4 M 19 M 20.7 M 18.2 M 14.7 M 14.6 M 15.8 M 15.1 M 12.1 M 11.7 M 12.4 M 11.8 M 9.76 M 9.42 M 10.1 M 9.67 M 8.07 M - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

18.7 M 18.1 M 16 M - 16 M 17.1 M 14.1 M 17.1 M 14.5 M 12 M 12.5 M 10.9 M 9.02 M 9.53 M 8.03 M - 9.06 M 7.95 M 4.85 M - 6.52 M 6.25 M 5.14 M - 4.57 M 3.53 M 4.14 M - 4.85 M 4.58 M 4 M - 3.84 M 3.81 M 3.18 M 8.83 M 2.88 M 3.09 M 2.35 M 6.4 M 2.98 M 6.83 M 5.98 M - - - - - - - - - - - - - - - - - - - -

Gross Profit

54 M 52.4 M 43.4 M - 45.3 M 44 M 38.3 M 35.6 M 40.1 M 40.8 M 32.2 M 26.7 M 31 M 30 M 23.6 M - 25.9 M 25 M 18.6 M 18.1 M 18.6 M 20.4 M 16.3 M 15.1 M 17.6 M 10.1 M 12.2 M 14.4 M 15.9 M 13.6 M 10.7 M 10.5 M 12 M 11.3 M 8.92 M 8.83 M 9.49 M 8.71 M 7.42 M - 7.16 M - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-4.22 M -4.07 M -8.34 M - -9.43 M -10.7 M -11 M -14.1 M -5.57 M -5.67 M -9.72 M -8.07 M -4.51 M -5.59 M -8.59 M - -6.96 M -3.74 M -6.39 M -5.56 M -3.64 M -2.85 M -5.97 M -12.7 M -2.5 M -7.02 M -4.5 M -3.03 M -1.54 M -1.79 M -2.72 M -1.87 M -1.17 M -2.12 M -4.4 M -4.2 M -754 K -677 K -837 K -3.25 M -524 K -865 K -1.49 M - - - - - - - - - - - - - - - - - - - -

Interest Expense

-11 K -333 K -421 K - -648 K 4.71 M 1.64 M -1.04 M 63 K -120 K 24 K 303 K -21 K -294 K 331 K - -945 K -1.21 M 105 K - 267 K -581 K 160 K - -122 K -121 K -69 K - -41 K -37 K - - -85 K -10 K -552 K - -761 K 61 K -445 K - 399 K - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-4.22 M 7.36 M -2.61 M - 6.09 M -10.7 M -5.93 M -14.1 M -286 K -5.67 M -4.7 M -8.07 M -238 K -5.59 M -4.74 M - 2.62 M -3.74 M -3.42 M -5.56 M 4.23 M -2.85 M -3.43 M -12.7 M 3.2 M -3.73 M -3.12 M -3.03 M 1.72 M 122 K -1.89 M -1.87 M 1 M -720 K -3.71 M -4.2 M 994 K 415 K -339 K -3.25 M 878 K -865 K -1.49 M - - - - - - - - - - - - - - - - - - - -

Operating Expenses

58.2 M 56.4 M 51.7 M - 54.7 M 54.7 M 49.2 M 49.6 M 45.6 M 46.5 M 41.9 M 34.8 M 35.5 M 35.6 M 32.2 M - 32.8 M 28.7 M 25 M 23.6 M 22.2 M 23.3 M 22.3 M 27.9 M 20.1 M 17.1 M 16.7 M 17.5 M 17.4 M 15.4 M 13.4 M 12.4 M 13.1 M 13.4 M 13.3 M 13 M 10.2 M 9.39 M 8.25 M - 7.68 M - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

32 M 32.8 M 31 M - 29.2 M 30.4 M 30.3 M 24.4 M 26.3 M 27.3 M 24.7 M 19.1 M 18 M 19.1 M 17.2 M - 15.1 M 14.5 M 13.2 M - 11 M 11.1 M 12 M - 9.82 M 10.6 M 7.88 M - 7.27 M 6.57 M 5.61 M - 4.88 M 5.5 M 6.02 M 6.69 M 3.49 M 3.42 M 3.37 M - 2.89 M - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements OrthoPediatrics Corp. KIDS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting OrthoPediatrics Corp. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Quanterix Corporation Quanterix Corporation
QTRX
$ 2.92 5.8 % $ 125 M usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 42.83 -4.03 % $ 63.4 B usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.47 3.01 % $ 3.69 M usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.93 -4.25 % $ 120 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 67.14 4.22 % $ 1.99 B costa-ricaCosta-rica
Delcath Systems Delcath Systems
DCTH
$ 14.95 3.17 % $ 536 M usaUSA
Electromed Electromed
ELMD
$ 26.94 1.4 % $ 223 M usaUSA
Inogen Inogen
INGN
$ 6.01 -11.23 % $ 160 M usaUSA
Globus Medical Globus Medical
GMED
$ 70.75 -13.21 % $ 9.57 B usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 85.54 -0.33 % $ 1.09 B usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 8.62 -0.81 % $ 244 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.11 -11.22 % $ 13.5 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
AxoGen AxoGen
AXGN
$ 49.95 2.46 % $ 2.3 B usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.68 -0.63 % $ 11.5 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 4.81 4.56 % $ 299 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 13.43 -4.89 % $ 1.03 B usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 61.34 5.7 % $ 9.31 B usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 90.02 -1.23 % $ 4.91 B britainBritain
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.22 4.94 % $ 218 M canadaCanada
LENSAR LENSAR
LNSR
$ 5.44 -1.09 % $ 65.1 M usaUSA
Orthofix Medical Orthofix Medical
OFIX
$ 7.87 -11.77 % $ 312 M curacaoCuracao
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 2.56 -0.59 % $ 104 M usaUSA
InspireMD InspireMD
NSPR
$ 0.71 11.49 % $ 45.7 M israelIsrael
InMode Ltd. InMode Ltd.
INMD
$ 13.34 -0.45 % $ 862 M israelIsrael
Outset Medical Outset Medical
OM
$ 4.24 3.41 % $ 64.5 M usaUSA
PAVmed PAVmed
PAVM
$ 1.58 1.61 % $ 1.06 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 16.6 5.87 % $ 462 M australiaAustralia
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 7.35 -0.81 % $ 993 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 63.96 -3.73 % $ 1.88 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 126.6 -0.11 % $ 4.4 B usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 1.95 0.78 % $ 43 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
FONAR Corporation FONAR Corporation
FONR
- - $ 140 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA